MediWound (NASDAQ:MDWD) Earns Sell Rating from Analysts at assumed coverage on shares of MediWound (NASDAQ:MDWDGet Rating) in a research report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on MDWD. Wells Fargo & Company raised their price objective on shares of MediWound to $8.00 and gave the company an “overweight” rating in a report on Wednesday, May 18th. Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of MediWound in a report on Monday, July 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.13.

MediWound Price Performance

MDWD stock opened at $1.67 on Monday. The stock has a market cap of $55.35 million, a price-to-earnings ratio of -3.27 and a beta of 1.14. The company has a 50 day simple moving average of $1.72 and a 200 day simple moving average of $1.99. MediWound has a 1 year low of $1.21 and a 1 year high of $4.11.

MediWound (NASDAQ:MDWDGet Rating) last announced its quarterly earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). MediWound had a negative net margin of 64.01% and a negative return on equity of 3,540.43%. The firm had revenue of $4.41 million during the quarter, compared to the consensus estimate of $4.35 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. On average, equities research analysts anticipate that MediWound will post -0.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Sargent Investment Group LLC lifted its holdings in MediWound by 40.0% in the second quarter. Sargent Investment Group LLC now owns 524,750 shares of the biopharmaceutical company’s stock valued at $966,000 after buying an additional 150,000 shares during the period. Warberg Asset Management LLC bought a new stake in MediWound in the first quarter worth approximately $44,000. Meitav Dash Investments Ltd. lifted its stake in MediWound by 56.1% in the first quarter. Meitav Dash Investments Ltd. now owns 306,538 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 110,129 shares during the period. Finally, We Are One Seven LLC bought a new position in shares of MediWound during the 4th quarter worth approximately $69,000. Institutional investors and hedge funds own 13.58% of the company’s stock.

MediWound Company Profile

(Get Rating)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Featured Articles

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with's FREE daily email newsletter.